Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Drop in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totaling 6,564,599 shares, a drop of 27.6% from the March 31st total of 9,069,811 shares. Currently, 13.1% of the shares of the stock are sold short. Based on an average daily volume of 788,190 shares, the short-interest ratio is presently 8.3 days.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH traded up $4.30 during midday trading on Thursday, hitting $87.80. The company’s stock had a trading volume of 428,090 shares, compared to its average volume of 962,246. The business’s 50 day simple moving average is $78.02 and its 200 day simple moving average is $54.67. The company has a market cap of $4.78 billion, a P/E ratio of -21.41 and a beta of 1.22. Dianthus Therapeutics has a 12-month low of $16.64 and a 12-month high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. On average, sell-side analysts predict that Dianthus Therapeutics will post -4.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Wells Fargo & Company assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, March 19th. They set an “overweight” rating and a $135.00 price objective on the stock. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Monday, March 9th. Truist Financial raised their price target on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 9th. Finally, Stifel Nicolaus set a $120.00 price target on shares of Dianthus Therapeutics in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Buy” and a consensus target price of $115.55.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, CEO Marino Garcia sold 122,918 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Ryan Savitz sold 114,367 shares of the stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total transaction of $9,492,461.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 323,021 shares of company stock valued at $26,564,008. 3.02% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently bought and sold shares of the company. First Horizon Corp purchased a new position in Dianthus Therapeutics during the first quarter worth about $32,000. Elevation Point Wealth Partners LLC purchased a new position in Dianthus Therapeutics during the first quarter worth about $409,000. Pictet Asset Management Holding SA purchased a new position in Dianthus Therapeutics during the first quarter worth about $413,000. Cannon Global Investment Management LLC purchased a new position in Dianthus Therapeutics during the first quarter worth about $428,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Dianthus Therapeutics during the fourth quarter worth about $43,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.